BRIEF—Odyssey armed with $168 more to advance portfolio

US biotech Odyssey Therapeutics has taken its total capital raised to $386 million.

This follows an oversubscribed $168 million Series B financing led by venture capital firm General Catalyst and adding to a $218 million Series A announced in December 2021.

The funds raised will allow Odyssey to advance its portfolio of precision immunomodulators and oncology medicines.

Odyssey’s immunology and oncology portfolio encompasses eight declared programs initially focused on small molecule and protein therapeutics.

The company is also building a discovery engine that integrates artificial intelligence and machine learning for molecular design, a chemistry platform encompassing proprietary covalent libraries targeting multiple amino acids, molecular glues and natural products, and a functional genomics platform for novel target discovery.